Ars Technicallustreams.comThe pills contain a drug called fluoroquinolone, which can make your body’s immune system more susceptible to certain infections, including those caused by viruses.
The drug is typically used for treating severe cases of the flu and other respiratory illnesses, and has a side effect of making the lungs more sensitive to cold.
But in this case, fluoroquinolone is also meant to treat milder cases of COVID-19, which usually doesn’t cause any symptoms.
As a result, it can sometimes make people more susceptible.
The FDA requires manufacturers to report the percentage of patients with fluoroqualone-containing pills that are reported to be healthy.
But the FDA doesn’t keep a list of people with fluorotic COVIDs.
It is unknown how many people have received the pills without symptoms.
The agency said that as of April, it had received 6,819 reports of fluoroqensolone-contaminated COVID patients.FDA data shows that a total of 5,539 patients were diagnosed with flu-related COVID cases, and that a further 1,039 cases have been treated with fluoxetine.
The agency has been unable to determine the percentage who have been given fluoro quinolones without symptoms, so it is unclear how many of the 6,724 patients with COVID are actually healthy.
The FDA said it will continue to monitor how many patients have been affected, but has not said how many were given the pills.
The pills are meant to reduce your risk of developing respiratory infections caused by COVID, which include pneumonia, bronchitis, and COPD.
They are sometimes also used to treat chronic bronchiolitis, a lung condition that can be triggered by breathing in fumes or other airborne pollutants.
The new study does not provide an exact estimate of how many pills have been distributed, but experts estimate that there are about 2.5 million pills in circulation worldwide.
The study was funded by the U.S. Agency for Healthcare Research and Quality (AHRQ), a division of the U: Health and Human Services Department.
The Associated Press contributed to this report.